Transfer Factor™ Study with 20 Cancer PatientsDarryl See, M.D. conducted the following Cancer Studies. Twenty patients, 12 men and 8 women, were selected for this in Vivo Study. The average age was 49.3

The twenty individuals were each level 3 or level 4 cancer patients. Each patient was basically sent home by his or her oncologist to die. The average life expectancy was 3.7 months. The protocol was to place each patient on 9 capsules per day of Transfer Factor Plus™.

The patients were given a number of other general nutrients*. After eight months, 16 of these individuals were still living and were either in remission, improving or stabilized.

The baseline for natural killer cell function was 6.4. Within 4 weeks the average NK Cell function was increased to 25.7 and in 6 months it increased to 27.6. This represented a 400% increase in NK Cell Function. This is an ongoing study. This study has been submitted to a peer reviewed publication.

Dr Darryl See,M.D :Associate Clinical Professor W.H.O. ( World Health Organization) Western Europe,  Dr. See received his degree from the University of California, Irvine.  Academic appointments include:  Assistant/Associate Clinical Professor of Medicine: Investigator, California Collaborative Treatment Group: and Infectious Disease Consultant, Liver Transplantation Service.

He has received contracts, grants, and research awards from Harvard Biotechnology, Pfizer Pharmaceuticals, Upjohn Pharmaceuticals, Roche Molecular Systems,, National Institutes of Health, Department of Defense, and more.

Info Kontak :

Sandur Budiman P

0812 860 88122

PIN BB 26CC698C

andu4life.blogspot.com